Lingrui Pharmaceutical (600285.SH) announced on September 13th that since its establishment, Jingyexing has maintained a good business development trend. In order to fully leverage the advantages of all parties, further expand the company's investment channels, and optimize the company's investment and business layout in technology innovation and domestic demand market through professional investment institutions, according to the company's strategic planning, the company intends to act as a limited partner of Jingyexing and add RMB 50 million of its own funds to subscribe for additional Jingyexing shares. After the additional investment, the company's cumulative subscribed amount in Jingyexing reaches RMB 150 million, accounting for 16.6667% of the total subscribed capital of Jingyexing.
羚锐制药(600285.SH)：拟以5000万元追加认购金镒兴份额
Henan Lingrui Pharmaceutical (600285.SH): Intends to invest an additional 50 million yuan to subscribe for more shares of Jinbaoxuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.